Search This Blog

Monday, March 15, 2021

China to raise retirement age in stages

 China plans to raise the retirement ages gradually over a number of years instead of in a drastic one-time change, a government researcher said last week, without providing any detail on when the changes might start.

When the retirement age starts being lifted, it will be by a few months every year, or by a month every few months, according to Jin Weigang, head of the Chinese Academy of Labor and Social Security under the Ministry of Human Resources and Social Security. Jin didn’t say when the changes would begin, but the current five-year plan calls for “raising the retirement age in a phased manner.”


“People in different age groups will be retiring at different ages,” Jin said in an interview with the state-run Xinhua News Agency published Saturday. “For example, in the first year of the policy’s implementation, female workers who were originally scheduled to retire at 50 will retire one month or a few months after 50.”

The policy should have a certain degree of flexibility to accommodate various kinds of workers’ desires to retire at different ages, Jin said. It will not be a “one-size-fit-all” plan and should leave room for individuals who wish to retire early, he said.

Jin’s comments give a rare glimpse into the official thinking behind the controversial proposal to postpone retirement, which was outlined in China’s 14th five-year plan as an antidote to the rapidly aging population and shrinking workforce. Male white-collar workers currently retire at 60 and females at 55, based on laws enacted in 1978.

https://www.bloomberg.com/news/articles/2021-03-15/china-to-raise-retirement-age-in-stages-state-researcher-says

INVO Bioscience Hits Key Milestone, to Open 1st US JV INVOcell Clinic

 INVO has partnered with experienced reproductive specialists who are strong advocates of the INVOcell solution

Clinic to be located in Birmingham, Alabama with a focus on providing INVOcell as an efficient, effective and affordable fertility treatment option for the very large underserved patient population in need of care

https://www.prnewswire.com/news-releases/invo-bioscience-achieves-key-milestone---signs-agreement-to-open-first-joint-venture-invocell-clinic-in-the-united-states-301247009.html

150 spring breakers arrested amid party chaos in Miami Beach

 About 150 people were arrested in Miami Beach over the weekend as throngs of unruly spring breakers descended on the city.

Friday marked the wildest day in the party hot spot as about 120 people were arrested and two police officers were injured during clashes with the revelers, Local 10 News reported.

“It is really a difficult situation,” Miami Beach Mayor Dan Gelber said of the weekend debauchery.

“A lot of people are coming here and they are coming here with the wrong intentions,” he said, according to another report from the outlet.

The city is under a midnight curfew amid the pandemic.

The officers who were injured had been attempting to make an arrest when they were attacked, authorities said.

“The crowd ended up turning on those officers who were there,” Miami Beach police spokesman Ernesto Rodriguez said, according to the report.

The gatherings on Friday led police in some areas to deploy pepper balls to disperse the crowds.

On Saturday, 30 more people were arrested.

Gelber warned would-be spring breakers that more arrests will be made if they continue to disobey laws.

“If you are coming here because you think anything goes, you’re going to have a terrible time. We are going to arrest you,” he said.

https://nypost.com/2021/03/15/150-spring-breakers-arrested-amid-party-chaos-in-miami-beach/

Timber Pharmaceuticals Announces 50% Enrollment in Phase 2b CONTROL Study

 - Study is Evaluating TMB-001 (Topical Isotretinoin) in Subtypes of Rare Genetic Keratinization Disorder 

- Company Awarded Final Tranche of $1.5 Million FDA Orphan Products Clinical Trials Grant   

Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that 50 percent of patients in the Phase 2b CONTROL study evaluating TMB-001 (topical isotretinoin) in patients with moderate to severe congenital ichthyosis (CI) have now been randomized. The Company also announced it has been awarded the final tranche of a $1.5 million grant from the U.S. Food & Drug Administration (FDA) Office of Orphan Products Development (OOPD) Orphan Products Clinical Trials Grants Program based on clinical milestones in the development of TMB-001.

“There are many rare dermatologic diseases that do not have any approved therapies and we are committed to advancing research focused on novel topical treatments that may enable targeted delivery to the epidermis and dermis while minimizing systemic absorption,” said Alan Mendelsohn, M.D., Chief Medical Officer of Timber. “People living with CI face many significant challenges in everyday life, not just physically but also with psychological well-being and self-esteem. Our success with enrolling the CONTROL study is a testament to the tremendous need for new treatment options. We are grateful to the patients who are participating and organizations like the Foundation for Ichthyosis & Related Skin Types (FIRST) that are helping raise awareness of this study amidst all the difficulties of the COVID-19 pandemic.” 

CI is a group of rare genetic keratinization disorders that leads to dry, thickened, and scaling skin. People living with CI may have limited range of motion, chronic itching, an inability to sweat normally, high risk of secondary infections, and impaired eyesight or hearing. Moderate to severe subtypes of CI, including X-linked ichthyosis and lamellar ichthyosis, affect about 80,000 people in the U.S. and more than 1.5 million globally.

The Phase 2b CONTROL study is a randomized, parallel, double-blind, vehicle-controlled study to assess the efficacy and safety of two concentrations of TMB-001 for the treatment of moderate to severe subtypes of CI. The study is targeting enrollment of 45 patients aged nine years old and older. 

https://www.globenewswire.com/news-release/2021/03/15/2192824/0/en/Timber-Pharmaceuticals-Announces-50-Enrollment-in-Phase-2b-CONTROL-Study-in-Congenital-Ichthyosis.html

Altimmune Single Dose, Intranasal COVID Vax Candidate, Prevents SARS-CoV-2 Disease, Blocks Replication in Preclinical

 New Findings from Ongoing Collaborations with University of Alabama at Birmingham and Saint Louis University

Studies Show Complete Protection Against Lethal Challenge and Dramatic Reduction in Viral Replication

Systemic and Mucosal Antibody Responses Durable for at Least 6 Months

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced additional preclinical data for its single dose intranasal COVID-19 vaccine candidate, AdCOVID. The preclinical studies were conducted at Altimmune’s collaborating institutions, the University of Alabama at Birmingham (UAB) and Saint Louis University (SLU).

The data, which were obtained in the K18-hACE2 transgenic mouse model, showed that a single intranasal dose of AdCOVID provided 100% protection against a lethal challenge from the SARS-CoV-2 virus. In these studies, which were performed in the laboratories of James Brien Ph.D., and Amelia Pinto Ph.D., within the Department of Molecular Microbiology & Immunology at SLU, all animals that received AdCOVID survived and had no observed weight loss. Initial immunogenicity analysis showed mean antibody levels of about 1 mg/mL, suggesting that the serum IgG antibody response against the spike protein was robust, similar to what was reported in prior Company announcements. In a separate study at UAB in the laboratory of Dr. Frances Lund that was conducted in the same animal model, a single intranasal dose of AdCOVID resulted in a greater than 1000-fold reduction in replicating virus in the nasal cavity and respiratory tract following infection with SARS-CoV-2.

https://www.globenewswire.com/news-release/2021/03/15/2192650/0/en/AdCOVID-Altimmune-s-Single-Dose-Intranasal-COVID-19-Vaccine-Candidate-Prevents-SARS-CoV-2-induced-Disease-and-Blocks-Viral-Replication-in-Preclinical-Studies-of-SARS-CoV-2-Infectio.html

Check-Cap Receives FDA IDE Approval for Pivotal Study of C-Scan

 Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan® , the first and only patient-friendly, preparation-free, screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) application, permitting Check-Cap to begin a pivotal study of C-Scan in the U.S. C-Scan is intended for candidates who are at average-risk for CRC and who are poor candidates for colonoscopy or decline colonoscopy, or who had an incomplete optical colonoscopy. The pivotal study will evaluate safety and performance of C-Scan as well as subject compliance with C-Scan.

"The IDE approval is a significant milestone for Check-Cap. Now with IDE in hand, we aim to enter the last phase of demonstrating the clinical potential of C-Scan in the U.S., with the ultimate goal of commercialization in this important market," said Alex Ovadia, Chief Executive Officer of Check-Cap. "We are in active discussions with a number of clinical sites as part of our preparations to begin the pivotal study in late 2021. In parallel, as previously communicated, we will be continuing to optimize C-Scan's performance and patient experience through additional clinical data collection at Israeli sites. To this end, we are gearing up to initiate a study in Israel at more than 10 clinical sites to enroll up to 250 average risk patients."

https://www.prnewswire.com/news-releases/check-cap-receives-fda-ide-approval-for-pivotal-study-of-c-scan-301247147.html

Roche agrees to buy GenMark Diagnostics for $1.8B

 Roche will buy GenMark Diagnostics, a U.S.-based maker of molecular diagnostic tests in a $1.8 billion deal, the Swiss pharmaceuticals manufacturer said on Monday.

Roche said it will launch a tender offer to fully acquire GenMark at a price of $24.05 per share in an all-cash transaction. The price represented a premium of 43% on GenMark's closing share price on Feb. 10, before media speculation about a deal, Roche said.

California-based GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample.

"Acquiring GenMark Diagnostics will broaden our molecular diagnostics portfolio to include solutions that can provide lifesaving information quickly to patients and their healthcare providers in the fight against infectious diseases," Roche Chief Executive Officer Thomas Schinecker said in a statement.

Roche said the acquisition, which has been approved by the boards of both companies, is expected to be completed during the second quarter of 2021.

Upon deal completion, GenMark's principal operations will continue at the current location in Carlsbad, California, Roche said. 

https://finance.yahoo.com/news/1-roche-agrees-buy-genmark-064453173.html